A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
Kenneth J CaldwellEsther De La CuestaCara E MorinAlberto S PappoSara HelmigPublished in: Pediatric blood & cancer (2020)
Infantile fibrosarcoma (IFS) is a rare pediatric cancer that typically presents early in life. Surgical resection is commonly curative; however, resection is sometimes not possible requiring additional multimodal treatment. IFS commonly harbors a fusion in one of the neurotrophic receptor tyrosine kinase (NTRK) genes. Larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase (TRK), has been shown to be well tolerated and effective in children as young as 1-month old. We report a case of IFS in a newborn treated with larotrectinib. The patient experienced a rapid clinical and radiographic response demonstrating the potential to treat newborns with larotrectinib.
Keyphrases
- tyrosine kinase
- epidermal growth factor receptor
- papillary thyroid
- young adults
- pregnant women
- case report
- genome wide
- binding protein
- middle aged
- rectal cancer
- cord blood
- squamous cell carcinoma
- gestational age
- lymph node metastasis
- low birth weight
- combination therapy
- protein kinase
- climate change
- preterm birth
- sensitive detection